Journal of Neurogastroenterology and Motility : eISSN 2093-0887 / pISSN 2093-0879

Cited by CrossRef (98)

  1. James S. Martin, Claire J. MacKenzie, Daniel Fletcher, Ian H. Gilbert. Characterising covalent warhead reactivity. Bioorganic & Medicinal Chemistry 2019;27:2066
    https://doi.org/10.1016/j.bmc.2019.04.002
  2. Abdrrahman Shemsu Surur, Lukas Schulig, Andreas Link. Interconnection of sulfides and sulfoxides in medicinal chemistry. Arch. Pharm. Chem. Life Sci. 2018:1800248
    https://doi.org/10.1002/ardp.201800248
  3. Dongyang Liu, Hong Yang, Ji Jiang, Péter Nagy, Kai Shen, Jiaming Qian, Pei Hu. Pharmacokinetic and Pharmacodynamic Modeling Analysis of Intravenous Esomeprazole in Healthy Volunteers. The Journal of Clinical Pharmacology 2016;56:816
    https://doi.org/10.1002/jcph.733
  4. M. Serratice, B. Bertrand, E. F. J. Janssen, E. Hemelt, A. Zucca, F. Cocco, M. A. Cinellu, A. Casini. Gold(i) compounds with lansoprazole-type ligands: synthesis, characterization and anticancer properties in vitro. Med. Chem. Commun. 2014;5:1418
    https://doi.org/10.1039/C4MD00241E
  5. Hideki Mori, Hidekazu Suzuki. Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker. J Neurogastroenterol Motil 2019;25:6
    https://doi.org/10.5056/jnm18139
  6. Jin-Young Min, Christopher J. Ocampo, Whitney W. Stevens, Caroline P.E. Price, Christopher F. Thompson, Tetsuya Homma, Julia H. Huang, James E. Norton, Lydia A. Suh, Kathryn L. Pothoven, David B. Conley, Kevin C. Welch, Stephanie Shintani-Smith, Anju T. Peters, Leslie C. Grammer, Kathleen E. Harris, Kathryn E. Hulse, Atsushi Kato, Nikolai N. Modyanov, Robert C. Kern, Robert P. Schleimer, Bruce K. Tan. Proton pump inhibitors decrease eotaxin-3/CCL26 expression in patients with chronic rhinosinusitis with nasal polyps: Possible role of the nongastric H,K-ATPase. Journal of Allergy and Clinical Immunology 2017;139:130
    https://doi.org/10.1016/j.jaci.2016.07.020
  7. Craig M. Lilly, Mohammad Aljawadi, Omar Badawi, Ebere Onukwugha, Sarah E. Tom, Laurence S. Magder, Ilene Harris. Comparative Effectiveness of Proton Pump Inhibitors vs Histamine Type 2 Receptor Blockers for Preventing Clinically Important Gastrointestinal Bleeding During Intensive Care. Chest 2018;154:557
    https://doi.org/10.1016/j.chest.2018.05.015
  8. Akiko Shiotani, Ryo Katsumata, Kyousuke  Gouda, Shinya Fukushima, Rui Nakato, Takahisa Murao, Manabu Ishii, Minoru Fujita, Hiroshi Matsumoto, Takashi Sakakibara. Hypergastrinemia in Long-Term Use of Proton Pump Inhibitors. Digestion 2018;97:154
    https://doi.org/10.1159/000484688
  9. King-Wah Chiu, Toshiaki Nakano, Kuang-Den Chen, Li-Wen Hsu, Chia-Yun Lai, Ching-Yin Huang, Yu-Fan Cheng, Shigeru Goto, Chao-Long Chen. Cytochrome P450 in living donor liver transplantation. J Biomed Sci 2015;22
    https://doi.org/10.1186/s12929-015-0140-4
  10. Luana Lugini, Cristina Federici, Martina Borghi, Tommaso Azzarito, Maria Lucia Marino, Albino Cesolini, Enrico Pierluigi Spugnini, Stefano Fais. Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect. Journal of Enzyme Inhibition and Medicinal Chemistry 2016;31:538
    https://doi.org/10.3109/14756366.2015.1046062
  11. Tadayuki Oshima, Hiroto Miwa. Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases. J Neurogastroenterol Motil 2018;24:334
    https://doi.org/10.5056/jnm18029
  12. Longgang Niu, Yu Liu, Xiaomin Hou, Lijuan Cui, Jiangtao Li, Xuanping Zhang, Mingsheng Zhang. Extracellular acidosis contracts coronary but neither renal nor mesenteric artery via modulation of H+,K+-ATPase, voltage-gated K+channels and L-type Ca2+channels. Exp Physiol 2014;99:995
    https://doi.org/10.1113/expphysiol.2014.078634
  13. Sung-Hwa Sohn, Nayoung Kim, Hyun Jin Jo, Jaeyeon Kim, Ji Hyun Park, Ryoung Hee Nam, Yeong-Jae Seok, Yeon-Ran Kim, Dong Ho Lee. Analysis of Gastric Body Microbiota by Pyrosequencing: Possible Role of Bacteria Other Than Helicobacter pylori in the Gastric Carcinogenesis. J Cancer Prev 2017;22:115
    https://doi.org/10.15430/JCP.2017.22.2.115
  14. Valentina Shakhnovich, P. Brian Smith, Jeffrey T. Guptill, Laura P. James, David N. Collier, Huali Wu, Chad E. Livingston, Jian Zhao, Gregory L. Kearns, Daniel K. Benjamin, Katherine Y. Berezny, P. Michael Cohen Wolkowiez, Matthew M. Laughon, Ian M. Paul, Michael J. Smith, John van den Anker, Kelly Wade, David Siegel, Perdita Taylor-Zapata, Anne Zajicek, Zhaoxia Ren, Ekaterini Tsilou, Alice Pagan, Ravinder Anand, Traci Clemons, Gina Simone, Lee Howard, Jaylene Weigel, Nancy Darden Saad. Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures. The Journal of Pediatrics 2018;193:102
    https://doi.org/10.1016/j.jpeds.2017.10.011
  15. Mustafa Abdul-Hussein, Janice Freeman, Donald Castell. Concomitant Administration of a Histamine2Receptor Antagonist and Proton Pump Inhibitor Enhances Gastric Acid Suppression. Pharmacotherapy 2015;35:1124
    https://doi.org/10.1002/phar.1665
  16. Yi Song, Fengna Dou, Zhe Zhou, Ningmin Yang, Jing Zhong, Jie Pan, Qiqi Liu, Jianzhong Zhang, Shengqi Wang. Microarray-Based Detection and Clinical Evaluation for Helicobacter pylori Resistance to Clarithromycin or Levofloxacin and the Genotype of CYP2C19 in 1083 Patients. BioMed Research International 2018;2018:1
    https://doi.org/10.1155/2018/2684836
  17. Johan Gabrielsson, Stephan Hjorth. Early Drug Development. 2018.
    https://doi.org/10.1002/9783527801756.ch14
  18. Olena Kis, Sharon L. Walmsley, Reina Bendayan. In Vitro and In Situ Evaluation of pH-Dependence of Atazanavir Intestinal Permeability and Interactions with Acid-Reducing Agents. Pharm Res 2014;31:2404
    https://doi.org/10.1007/s11095-014-1336-0
  19. Hsun Yang, Shiun-Yang Juang, Kuan-Fu Liao. Proton pump inhibitors use and risk of chronic kidney disease in diabetic patients. Diabetes Research and Clinical Practice 2019;147:67
    https://doi.org/10.1016/j.diabres.2018.11.019
  20. Yugo Hamada, Kenji Ikemura, Takuya Iwamoto, Masahiro Okuda. Stereoselective Inhibition of Renal Basolateral Human Organic Anion Transporter 3 by Lansoprazole Enantiomers. Pharmacology 2018;101:176
    https://doi.org/10.1159/000485920
  21. Dragos Apostu, Ondine Lucaciu, Gheorghe Dan Osvald Lucaciu, Bogdan Crisan, Liana Crisan, Mihaela Baciut, Florin Onisor, Grigore Baciut, Radu Septimiu Câmpian, Simion Bran. Systemic drugs that influence titanium implant osseointegration. Drug Metabolism Reviews 2017;49:92
    https://doi.org/10.1080/03602532.2016.1277737
  22. Timothy P. Shiraev, Andrew Bullen. Proton Pump Inhibitors and Cardiovascular Events: A Systematic Review. Heart, Lung and Circulation 2018;27:443
    https://doi.org/10.1016/j.hlc.2017.10.020
  23. Xiaoxiao Yang, Yueyue Li, Yiyuan Sun, Mingming Zhang, Chuanguo Guo, Iqtida Ahmed Mirza, Yan-Qing Li. Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases. Dig Dis Sci 2018;63:302
    https://doi.org/10.1007/s10620-017-4866-6
  24. Carine Franco Morschel, Denise Mafra, José Carlos Carraro Eduardo. The relationship between proton pump inhibitors and renal disease. J. Bras. Nefrol. 2018;40:301
    https://doi.org/10.1590/2175-8239-jbn-2018-0021
  25. Saswati Bhattacharya, Jasmina Khanam, Pradipta Sarkar, Tapan Kumar Pal. A chemotherapeutic approach targeting the acidic tumor microenvironment: combination of a proton pump inhibitor and paclitaxel for statistically optimized nanotherapeutics. RSC Adv. 2019;9:240
    https://doi.org/10.1039/C8RA08924H
  26. Vincent H Ha, Margaret Ngo, Michael P Chu, Sunita Ghosh, Michael B Sawyer, Carole R Chambers. Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer?. J Oncol Pharm Pract 2015;21:194
    https://doi.org/10.1177/1078155214527145
  27. D. B. Stewart, J. P. Hegarty. Correlation between virulence gene expression and proton pump inhibitors and ambient pH in Clostridium difficile: results of an in vitro study. Journal of Medical Microbiology 2013;62:1517
    https://doi.org/10.1099/jmm.0.059709-0
  28. S. Šutalo, M. Ruetten, S. Hartnack, C.E. Reusch, P. H. Kook. The Effect of Orally Administered Ranitidine and Once-Daily or Twice-Daily Orally Administered Omeprazole on Intragastric pH in Cats. J Vet Intern Med 2015;29:840
    https://doi.org/10.1111/jvim.12580
  29. Chuan Tian, Lixin Zhu, Dan Yu, Zhiwei Cao, Tingguo Kang, Ruixin Zhu. The Stereoselectivity of CYP2C19 on R- and S-isomers of Proton Pump Inhibitors. Chem Biol Drug Des 2014;83:610
    https://doi.org/10.1111/cbdd.12274
  30. Megan Walsh, Stefano Fais, Enrico Pierluigi Spugnini, Salvador Harguindey, Tareq Abu Izneid, Licia Scacco, Paula Williams, Cinzia Allegrucci, Cyril Rauch, Ziad Omran. Proton pump inhibitors for the treatment of cancer in companion animals. J Exp Clin Cancer Res 2015;34
    https://doi.org/10.1186/s13046-015-0204-z
  31. G. Sachs, E. A. Marcus, Y. Wen, K. Munson. Editorial: control of acid secretion. Aliment Pharmacol Ther 2018;48:682
    https://doi.org/10.1111/apt.14864
  32. Ryoko Toda, Tomoharu Miyagawa, Yuka Masuda, Yusuke Hoshino, Kazuyoshi Yoshii, Masamichi Hirayama, Minaka Shibuya, Yoshihiro Kawabata. Mass balance and metabolism of Z-215, a novel proton pump inhibitor, in healthy volunteers. Xenobiotica 2018;48:1006
    https://doi.org/10.1080/00498254.2017.1390625
  33. Hashem Ahmadizadegan, Mahdi Ranjbar, Sheida Esmaielzadeh. Synthesis and characterization of green membranes polyimide/titania bionanocomposites containing amino acid and benzimidazole moieties for gas transport properties. Polym Eng Sci 2018;58:1666
    https://doi.org/10.1002/pen.24757
  34. Hua-Ching Chang, Yin-Shuo Chang, Kuo-Hsien Wang, Tiong Cheng, Hsiou-Hsin Tsai. Esomeprazole-induced ashy dermatosis-like drug eruptions. Australas J Dermatol 2018
    https://doi.org/10.1111/ajd.12978
  35. J.M. Remes-Troche, F.D. García García, G. Rojas-Loureiro, X. Rivera-Gutiérrez, J. Reyes-Huerta, M. Amieva-Balmori. Efecto sobre el pH intragástrico de 20 mg de levopantoprazol versus 40 mg de pantoprazol racémico durante los primeros 7 días de tratamiento en pacientes con enfermedad por reflujo gastroesofágico. Revista de Gastroenterología de México 2019
    https://doi.org/10.1016/j.rgmx.2019.02.006
  36. Annamaria Tonazzi, Ivano Eberini, Cesare Indiveri, Gabriele Vincenzo Gnoni. Molecular Mechanism of Inhibition of the Mitochondrial Carnitine/Acylcarnitine Transporter by Omeprazole Revealed by Proteoliposome Assay, Mutagenesis and Bioinformatics. PLoS ONE 2013;8:e82286
    https://doi.org/10.1371/journal.pone.0082286
  37. Philip Woodland, Gehanjali Amarasinghe, Daniel Sifrim. Emerging therapeutic options in GERD. Best Practice & Research Clinical Gastroenterology 2013;27:455
    https://doi.org/10.1016/j.bpg.2013.06.006
  38. Tatjana Bosnjak, Rigmor Solberg, Paya Diana Hemati, Abbas Jafari, Moustapha Kassem, Harald Thidemann Johansen. Lansoprazole inhibits the cysteine protease legumain by binding to the active site. Basic Clin Pharmacol Toxicol 2019
    https://doi.org/10.1111/bcpt.13230
  39. Gautham Yepuri, Roman Sukhovershin, Timo Z. Nazari-Shafti, Michael Petrascheck, Yohannes T. Ghebre, John P. Cooke. Proton Pump Inhibitors Accelerate Endothelial Senescence. Circ Res 2016;118
    https://doi.org/10.1161/CIRCRESAHA.116.308807
  40. Yoon Jin Choi, Nayoung Kim, In-Jin Jang, Joo-Youn Cho, Ryoung Hee Nam, Ji Hyun Park, Hyun Jin Jo, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee, Hyun Chae Jung. Pantoprazole Does Not Reduce the Antiplatelet Effect of Clopidogrel: A Randomized Controlled Trial in Korea. Gut and Liver 2017;11:504
    https://doi.org/10.5009/gnl16352
  41. Madeleine Strickland, Lorna S. Ehrlich, Susan Watanabe, Mahfuz Khan, Marie-Paule Strub, Chi-Hao Luan, Michael D. Powell, Jonathan Leis, Nico Tjandra, Carol A. Carter. Tsg101 chaperone function revealed by HIV-1 assembly inhibitors. Nat Commun 2017;8
    https://doi.org/10.1038/s41467-017-01426-2
  42. Hsiu-Chen Lin, Yu-Ting Hsiao, Hsiu-Li Lin, Yow-Shieng Uang, Hui-Wen Cheng, Ying Wang, Li-Hsuan Wang. The use of proton pump inhibitors decreases the risk of diabetes mellitus in patients with upper gastrointestinal disease. Medicine 2016;95:e4195
    https://doi.org/10.1097/MD.0000000000004195
  43. Ning-Ning Liu, Julia R. Köhler. Antagonism of Fluconazole and a Proton Pump Inhibitor against Candida albicans. Antimicrob. Agents Chemother. 2016;60:1145
    https://doi.org/10.1128/AAC.02043-15
  44. Alexandru Mester, Dragos Apostu, Lidia Ciobanu, Andra Piciu, Ondine Lucaciu, Radu Septimiu Campian, Marian Taulescu, Simion Bran. The impact of proton pump inhibitors on bone regeneration and implant osseointegration. Drug Metabolism Reviews 2019:1
    https://doi.org/10.1080/03602532.2019.1610767
  45. BYUNG KIL CHOO, SEONG-SOO ROH. Berberine protects against esophageal mucosal damage in reflux esophagitis by suppressing proinflammatory cytokines. 2013;6:663
    https://doi.org/10.3892/etm.2013.1202
  46. Tanzila Arshad, Khalid Mohammed Khan, Najma Rasool, Uzma Salar, Shafqat Hussain, Humna Asghar, Mohammed Ashraf, Abdul Wadood, Muhammad Riaz, Shahnaz Perveen, Muhammad Taha, Nor Hadiani Ismail. 5-Bromo-2-aryl benzimidazole derivatives as non-cytotoxic potential dual inhibitors of α -glucosidase and urease enzymes. Bioorganic Chemistry 2017;72:21
    https://doi.org/10.1016/j.bioorg.2017.03.007
  47. Tigran Makunts, Isaac V. Cohen, Linda Awdishu, Ruben Abagyan. Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis. Sci Rep 2019;9
    https://doi.org/10.1038/s41598-019-39335-7
  48. Hao Wang, Yantong Sun, Yan Yang, Wei Guo, Mi Zheng, Weiping Zhang, J Paul Fawcett, Jingkai Gu. Application of a high-throughput, parallel HPLC system for quantitative chiral analysis of pantoprazole. Bioanalysis 2015;7:2981
    https://doi.org/10.4155/bio.15.215
  49. M. Srinivas, S. Satyaveni, B. Ram. Synthesis and Anticancer Activity of 1,2,4-Oxadiazol Linked Benzimidazole Derivatives. Russ J Gen Chem 2018;88:2653
    https://doi.org/10.1134/S1070363218120289
  50. Sara Granja, Diana Tavares-Valente, Odília Queirós, Fátima Baltazar. Value of pH regulators in the diagnosis, prognosis and treatment of cancer. Seminars in Cancer Biology 2017;43:17
    https://doi.org/10.1016/j.semcancer.2016.12.003
  51. Kentaro Sugano. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therap Adv Gastroenterol 2018;11:1756283X1774577
    https://doi.org/10.1177/1756283X17745776
  52. S Setiadji, C D D Sundari, M A Ramdhani, A B K Umam, A L Ivansyah. Theoretical Investigation of Inclusion Complex between Omeprazole Enantiomers and Carboxymethyl-β-Cyclodextrin. IOP Conf. Ser.: Mater. Sci. Eng. 2018;288:012138
    https://doi.org/10.1088/1757-899X/288/1/012138
  53. Ran Li, Xiaoyun Chai, Xiaoyan Cui, Yuanying Jiang, Dazhi Zhang, Ting Wang. A fluorescence resonance energy transfer based pH probe for visualizing acidification in fungal cells. Sensors and Actuators B: Chemical 2018;274:533
    https://doi.org/10.1016/j.snb.2018.07.134
  54. J. P. Moraes-Filho, M. Pedroso, E. M. M. Quigley. Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms. Aliment Pharmacol Ther 2014;39:47
    https://doi.org/10.1111/apt.12540
  55. S. Tommasi, D. J. Elliot, J. A. Hulin, B. C. Lewis, M. McEvoy, A. A. Mangoni. Human dimethylarginine dimethylaminohydrolase 1 inhibition by proton pump inhibitors and the cardiovascular risk marker asymmetric dimethylarginine: in vitro and in vivo significance. Sci Rep 2017;7
    https://doi.org/10.1038/s41598-017-03069-1
  56. Óskar Ö. Hálfdánarson, Katja Fall, Margret H. Ogmundsdottir, Sigrún H. Lund, Eiríkur Steingrímsson, Helga M. Ogmundsdottir, Helga Zoega. Proton pump inhibitor use and risk of breast cancer, prostate cancer, and malignant melanoma: An Icelandic population‐based case‐control study. Pharmacoepidemiol Drug Saf 2019;28:471
    https://doi.org/10.1002/pds.4702
  57. Yvonne Y. Lau, Wen Gu, Tiffany Lin, Kalyanee Viraswami-Appanna, Can Cai, Jeffrey W. Scott, Michael Shi. Assessment of drug–drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer. Cancer Chemother Pharmacol 2017;79:1119
    https://doi.org/10.1007/s00280-017-3308-7
  58. Nayoung Kim, Yoon Jin Choi. Helicobacter pylori. 2017.
    https://doi.org/10.1007/978-981-287-706-2_4
  59. Yingxi Chen, Bette Liu, Kathryn Glass, Wei Du, Emily Banks, Martyn Kirk, John Green. Use of Proton Pump Inhibitors and the Risk of Hospitalization for Infectious Gastroenteritis. PLoS ONE 2016;11:e0168618
    https://doi.org/10.1371/journal.pone.0168618
  60. Caroline Race, Joanna Chowdry, Jean M. Russell, Bernard M. Corfe, Stuart A. Riley. Studies of salivary pepsin in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2019;49:1173
    https://doi.org/10.1111/apt.15138
  61. Young Kwang Shim, Nayoung Kim. The Effect of H2 Receptor Antagonist in Acid Inhibition and Its Clinical Efficacy. Korean J Gastroenterol 2017;70:4
    https://doi.org/10.4166/kjg.2017.70.1.4
  62. Flávia Almeida Santos, Vietla Satyanarayana Rao. Sistema Digestório: Integração Básico-Clínica. 2017.
    https://doi.org/10.5151/9788580391893-23
  63. K. Renuka Prasad, Priyanka Chettri, N. A. Rajesh, A. Rathinaswamy, R. Padmanaban, T. M. Vijayakumar. Assessment of the risk of acute kidney injury associated with the use of pantoprazole and esomeprazole. Drugs Ther Perspect 2018;34:223
    https://doi.org/10.1007/s40267-018-0503-5
  64. Krista L. Niece, Natalie K. Boyd, Kevin S. Akers. In VitroStudy of the Variable Effects of Proton Pump Inhibitors on Voriconazole. Antimicrob. Agents Chemother. 2015;59:5548
    https://doi.org/10.1128/AAC.00884-15
  65. Artem Minalyan, Lilit Gabrielyan, David Scott, Jonathan Jacobs, Joseph R. Pisegna. The Gastric and Intestinal Microbiome: Role of Proton Pump Inhibitors. Curr Gastroenterol Rep 2017;19
    https://doi.org/10.1007/s11894-017-0577-6
  66. Nihal El Rouby, John J. Lima, Julie A. Johnson. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opinion on Drug Metabolism & Toxicology 2018;14:447
    https://doi.org/10.1080/17425255.2018.1461835
  67. Antonio Pirodda, Maria Chiara Raimondi, Arrigo Francesco Giuseppe Cicero, Martina Rosticci, Elisa Rebecca Rinaldi, Lara Bellacosa, Vincenzo Stanghellini, Claudio Borghi. Tinnitus in patients on therapy with proton pump inhibitors (PPI) and in PPI non-users. Hearing, Balance and Communication 2014;12:84
    https://doi.org/10.3109/21695717.2014.902554
  68. Shuqin Zhou, Debra J. Skaar, Pamala A. Jacobson, R. Stephanie Huang. Pharmacogenomics of Medications Commonly Used in the Intensive Care Unit. Front. Pharmacol. 2018;9
    https://doi.org/10.3389/fphar.2018.01436
  69. Michael Kukulka, Sai Nudurupati, Maria Claudia Perez. Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole. Therap Adv Gastroenterol 2016;9:759
    https://doi.org/10.1177/1756283X16670073
  70. Roman A. Sukhovershin, John P. Cooke. How May Proton Pump Inhibitors Impair Cardiovascular Health?. Am J Cardiovasc Drugs 2016;16:153
    https://doi.org/10.1007/s40256-016-0160-9
  71. Lateef Ahmad, Zafar Iqbal, Yasar Shah, D. G. Watson, Abad Khan, Muhammad Imran Khan, Fazli Khuda, Abbas Khan, Fazli Nasir. Simple and Fast Liquid Chromatography–Mass Spectrometry (LC–MS) Method for the Determination of Omeprazole, 5-hydroxyomeprazole, and Omeprazole Sulphone in Human Plasma. Journal of Liquid Chromatography & Related Technologies 2015;38:692
    https://doi.org/10.1080/10826076.2014.951763
  72. Elise Pape, Delphine Michel, Julien Scala-Bertola, Thomas Schiestel, Alexandre Harlé, Stéphane Bouchet, Audrey Contet, Cécile Pochon, Nicolas Gambier. Effect of esomeprazole on the oral absorption of dasatinib in a patient with Philadelphia-positive acute lymphoblastic leukemia. Br J Clin Pharmacol 2016;81:1195
    https://doi.org/10.1111/bcp.12895
  73. Raimunda SN Brilhante, Maria G da Rocha, Jonathas S de Oliveira, Jaime DA España, Vandbergue S Pereira, Débora de SCM Castelo-Branco, Waldemiro de A Pereira-Neto, José JC Sidrim, Rossana de A Cordeiro, Marcos FG Rocha. Proton pump inhibitors versus Cryptococcus species: effects on in vitro susceptibility and melanin production. Future Microbiology 2019;14:489
    https://doi.org/10.2217/fmb-2018-0340
  74. Ana Ruiz-Garcia, Joanna C. Masters, Laure Mendes da Costa, Robert R. LaBadie, Yali Liang, Grace Ni, Craig A. Ellery, Tanya Boutros, Zelanna Goldberg, Carlo L. Bello. Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers. The Journal of Clinical Pharmacology 2016;56:223
    https://doi.org/10.1002/jcph.588
  75. Gloria Ortiz-Guerrero, Diana Amador-Muñoz, Carlos Alberto Calderón-Ospina, Daniel López-Fuentes, Mauricio Orlando Nava Mesa. Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical Consequences. Neural Plasticity 2018;2018:1
    https://doi.org/10.1155/2018/5257285
  76. Jin Liu, Ning Huang, Ning Li, Si-Nian Liu, Min-Hui Li, Hua Li, Xing-Yan Luo, Yan-Tang Wang, Li-Mei Li, Qiang Zou, Yang Liu, Tai Yang. 2-(1H-Benzimidazol-2-yl)-4,5,6,7-tetrahydro-2H-indazol-3-ol, a Benzimidazole Derivative, Inhibits T Cell Proliferation Involving H+/K+-ATPase Inhibition. Molecules 2014;19:17173
    https://doi.org/10.3390/molecules191117173
  77. Neda O. Anastassova, Anelia Ts. Mavrova, Denitsa Y. Yancheva, Magdalena S. Kondeva-Burdina, Virginia I. Tzankova, Simeon S. Stoyanov, Boris L. Shivachev, Rositsa P. Nikolova. Hepatotoxicity and antioxidant activity of some new N,N′-disubstituted benzimidazole-2-thiones, radical scavenging mechanism and structure-activity relationship. Arabian Journal of Chemistry 2018;11:353
    https://doi.org/10.1016/j.arabjc.2016.12.003
  78. Samaneh Soleymani, Roodabeh Bahramsoltani, Roja Rahimi, Mohammad Abdollahi. Clinical risks of St John’s Wort (Hypericum perforatum) co-administration. Expert Opinion on Drug Metabolism & Toxicology 2017;13:1047
    https://doi.org/10.1080/17425255.2017.1378342
  79. Andrea Canitano, Elisabetta Iessi, Enrico Pierluigi Spugnini, Cristina Federici, Stefano Fais. Proton pump inhibitors induce a caspase-independent antitumor effect against human multiple myeloma. Cancer Letters 2016;376:278
    https://doi.org/10.1016/j.canlet.2016.04.015
  80. Kyu-Nam Kim, Sung-Won Yang, Hyunil Kim, Seong Shin Kwak, Young-Sang Kim, Doo-Yeoun Cho. Acid Inhibitory Effect of a Combination of Omeprazole and Sodium Bicarbonate (CDFR0209) Compared With Delayed-Release Omeprazole 40 mg Alone in Healthy Adult Male Subjects. Clinical Pharmacology in Drug Development 2018;7:53
    https://doi.org/10.1002/cpdd.331
  81. Yunju Jo, Eunkyoung Park, Sang Bong Ahn, Young Kwan Jo, Byungkwan Son, Seong Hwan Kim, Young Sook Park, Hyo Jeong Kim. A Proton Pump Inhibitor's Effect on Bone Metabolism Mediated by Osteoclast Action in Old Age: A Prospective Randomized Study. Gut Liver 2015;9
    https://doi.org/10.5009/gnl14135
  82. Youssef Rouphael, Giampaolo Raimondi, Luigi Lucini, Petronia Carillo, Marios C. Kyriacou, Giuseppe Colla, Valerio Cirillo, Antonio Pannico, Christophe El-Nakhel, Stefania De Pascale. Physiological and Metabolic Responses Triggered by Omeprazole Improve Tomato Plant Tolerance to NaCl Stress. Front. Plant Sci. 2018;9
    https://doi.org/10.3389/fpls.2018.00249
  83. Adam Chwiesko, Radoslaw Charkiewicz, Jacek Niklinski, Wojciech Luczaj, Elzbieta Skrzydlewska, Robert Milewski, Andrzej Baniukiewicz, Eugeniusz Wroblewski, Mariusz Rosolowski, Andrzej Dabrowski. Effects of different omeprazole dosing on gastric pH in non-variceal upper gastrointestinal bleeding: A randomized prospective study. Journal of Digestive Diseases 2016;17:588
    https://doi.org/10.1111/1751-2980.12393
  84. Mehmet Aslan, Yilmaz Celik, Sevdegul Karadas, Sehmus Olmez, Adem Cifci. Liver hepatotoxicity associated with pantoprazole: a rare case report. Wien Klin Wochenschr 2014;126:390
    https://doi.org/10.1007/s00508-014-0535-3
  85. Yuuichi Sakurai, Madoka Shiino, Hiroyuki Okamoto, Akira Nishimura, Koki Nakamura, Setsuo Hasegawa. Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study. Adv Ther 2016;33:1519
    https://doi.org/10.1007/s12325-016-0374-x
  86. Saifur Rahman, Taufiq Rahman. Unveiling some FDA-approved drugs as inhibitors of the store-operated Ca2+ entry pathway. Sci Rep 2017;7
    https://doi.org/10.1038/s41598-017-13343-x
  87. A. M. Amin, M. M. Omar, S. M. Abd-elhaliem, A. A. Elshanawany. Gastric ulcer localization: Potential use of 125I-omeprazole as radiotracer. Radiochemistry 2015;57:182
    https://doi.org/10.1134/S1066362215020113
  88. Miao Yan, Zhu-feng Wu, Dan Tang, Feng Wang, Yi-wen Xiao, Ping Xu, Bi-kui Zhang, Yi-ping Liu, Da-xiong Xiang, Hoan Linh Banh. The impact of proton pump inhibitors on the pharmacokinetics of voriconazole in vitro and in vivo. Biomedicine & Pharmacotherapy 2018;108:60
    https://doi.org/10.1016/j.biopha.2018.08.121
  89. Prashanth Porayette, David Flockhart, Sandeep K. Gupta. One Size Fits One: Pharmacogenetics in Gastroenterology. Clinical Gastroenterology and Hepatology 2014;12:565
    https://doi.org/10.1016/j.cgh.2014.01.035
  90. TAI YANG, MIN-HUI LI, JIN LIU, NING HUANG, NING LI, SI-NIAN LIU, YANG LIU, TAO ZHANG, QIANG ZOU, HUA LI. Benzimidazole derivative, BMT-1, induces apoptosis in multiple myeloma cells via a mitochondrial-mediated pathway involving H+/K+-ATPase inhibition. 2014;31:2743
    https://doi.org/10.3892/or.2014.3122
  91. Nobuhiro Inatomi, Jun Matsukawa, Yuuichi Sakurai, Kazuyoshi Otake. Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases. Pharmacology & Therapeutics 2016;168:12
    https://doi.org/10.1016/j.pharmthera.2016.08.001
  92. Man Yu, Carol Lee, Marina Wang, Ian F. Tannock. Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors. Cancer Sci 2015;106:1438
    https://doi.org/10.1111/cas.12756
  93. Kenji Ikemura, Shunichi Hiramatsu, Masahiro Okuda. Drug Repositioning of Proton Pump Inhibitors for Enhanced Efficacy and Safety of Cancer Chemotherapy. Front. Pharmacol. 2017;8
    https://doi.org/10.3389/fphar.2017.00911
  94. Michael Kukulka, Sai Nudurupati, Maria Claudia Perez. Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule. Therap Adv Gastroenterol 2016;9:770
    https://doi.org/10.1177/1756283X16666800
  95. Emre Yucel, Mesut Sancar, Aylin Yucel, Betul Okuyan. Adverse drug reactions due to drug–drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method. Expert Opinion on Drug Safety 2016;15:223
    https://doi.org/10.1517/14740338.2016.1128413
  96. Yusmiati Yusmiati, Dewi Muliaty. The Pharmacogenetics of Cytochrome P450 2C19 Enzymes - Effects on Clopidogrel and Proton Pump Inhibitors. Indones Biomed J 2014;6:33
    https://doi.org/10.18585/inabj.v6i1.41
  97. Chih-Ming Liang, Ming-Te Kuo, Pin-I Hsu, Chao-Hung Kuo, Wei-Chen Tai, Shih-Cheng Yang, Keng-Liang Wu, Hsing-Ming Wang, Chih-Chien Yao, Cheng-En Tsai, Yao-Kuang Wang, Jiunn-Wei Wang, Chih-Fang Huang, Deng-Chyang Wu. First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease. WJG 2017;23:8395
    https://doi.org/10.3748/wjg.v23.i47.8395
  98. Benjamin Ka Seng Thong, Soelaiman Ima-Nirwana, Kok-Yong Chin. Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved. IJERPH 2019;16:1571
    https://doi.org/10.3390/ijerph16091571